Invenra Welcomes Three Industry Leaders to Its Board of Directors
2024年9月18日 - 2:48AM
ビジネスワイヤ(英語)
Invenra Inc. is pleased to announce the addition of three
distinguished professionals to its Board of Directors: Saira
Ramasastry, Heather Preston, MD, and William Hinshaw. Together,
these leaders bring decades of expertise in life sciences,
encompassing clinical development, biotherapeutic
commercialization, and strategic growth within the biotechnology
industry.
Saira Ramasastry has over 25 years of experience in the
life sciences, successfully building companies as an advisor, board
member, and operational executive. She is the Managing Partner of
Life Sciences Advisory, a firm she founded to provide strategic
advice to life sciences companies. Previously, she was an
investment banker with Merrill Lynch & Co., where she helped
establish the biotech practice to support capital market and
strategic transactions. Ms. Ramasastry is a guest lecturer for the
Bioscience Enterprise Program at the University of Cambridge and a
Health Innovator Fellow at the Aspen Institute. She earned her B.A.
in Economics with Honors and Distinction from Stanford University,
graduating Phi Beta Kappa, and holds advanced degrees in Management
Science and Engineering from Stanford and in Management Studies
from the University of Cambridge.
Heather Preston, MD is an experienced healthcare venture
capitalist and company builder with more than 30 years of industry
experience. She currently serves as a Senior Advisor to TPG Biotech
and sits on the Boards of Oxford Biomedica (OXB; LSE), Oxford
Nanopore Technologies (ONT; LSE), Aligos Therapeutics (ALGS;
Nasdaq), and Azura Ophthalmics. Previously, she was a Managing
Partner of Pivotal Bioventures and a Firm Partner and Managing
Director of TPG Biotech. Dr. Preston also held investing roles at
JP Morgan Partners and New Enterprise Associates. Before her
investing career, she spent five years at McKinsey & Co., where
she led the pharmaceutical and medical products consulting
practice. Dr. Preston holds an undergraduate degree in biochemistry
from the University of London and a medical degree from the
University of Oxford. She completed a post-doctoral fellowship in
molecular biology at the Dana-Farber Cancer Institute, Harvard
University, and trained in Internal Medicine at Massachusetts
General Hospital, and subspecialized in Gastroenterology and
Hepatology at UCSF. During her academic medical career, she
received a Fulbright Scholarship, a Fulbright Cancer Research
Scholarship, a Harlech Scholarship, and a Science and Engineering
Research Council Post-Doctoral Fellowship Award.
William Hinshaw brings over 30 years of experience in the
biotechnology and pharmaceutical industries. He currently serves as
CEO of Fore Biotherapeutics, a precision oncology company. His
prior roles include President and CEO of Axcella Therapeutics,
where he spearheaded the development of novel therapies for complex
diseases. At Novartis, he led the U.S. Oncology business,
overseeing flagship products such as Tasigna®, Gleevec®, and
Kymriah®, and played a key role in integrating the GSK oncology
portfolio. He also led the oncology business in 33 European
countries and global infectious disease and transplant business as
well as all Novartis businesses across 90 countries. Mr. Hinshaw
began his career at Schering-Plough Corporation in various
commercial roles, eventually serving as Head of U.S. Oncology. He
holds a B.S. in Molecular Biology from the University of
Wisconsin.
"We are excited to welcome Saira, Heather, and Bill to our
Board," said Roland Green, CEO and Chairman of Invenra. "Their
remarkable achievements in biotherapeutics development,
commercialization, and strategic leadership align perfectly with
Invenra's mission to advance novel bispecific antibody-based
therapeutics. Their insights and guidance will be pivotal as we
forge new strategic partnerships and expand our therapeutic
portfolio."
About Invenra
Invenra is a leading bispecific antibody technology company,
committed to delivering groundbreaking therapies to patients
worldwide. Our proprietary B-Body® Platform offers significant
advantages in discovery, manufacturing, and formulation, with true
"Plug & Play" performance for rapid therapeutic engineering.
Invenra’s portfolio of wholly owned and partnered molecules
positions us at the forefront of therapeutic innovation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240917576990/en/
Bryan Glaser Senior Vice President, Business Development Invenra
Inc. 608-441-8319 bglaser@invenra.com